CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 27, 2006--Molecular Insight Pharmaceuticals, Inc. today announced the start of a Phase 2 clinical trial to develop a reference database of normal Zemiva(TM) images of the heart using SPECT imaging. The normative trial is part of Molecular Insight’s ongoing clinical program to develop Zemiva(TM) (iodofiltic acid I 123) for the diagnosis of cardiac ischemia in chest pain patients in the emergency department setting. Currently, an estimated six to eight million chest pain patients in the United States require determination of whether their chest pain is caused by insufficient blood flow to the heart each year. Tools such as a Normals reference database are commonly used in the field of nuclear cardiology to enable an interpreting physician to compare a patient’s cardiac image against that of a population-based “normal” image.
